“…In search of pharmacological agents that suppress the biosynthesis of LTs, different types of small molecular inhibitors of 5-LOX have been developed in the past two decades, such as redox inhibitors, iron-chelator agents and non-redox competitive inhibitors 10 , 11 . To date, despite considerable efforts devoted to the development of efficient and safe drugs that target the 5-LOX pathway, only one 5-LOX inhibitor, Zileuton ( 1 , Scheme 1 ), has been approved for asthma treatment 12 , although it still exhibits several drawbacks, including liver toxicity and unfavorable pharmacokinetic profile with a short half-life 3 .…”